News Headlines Article

ALS patients get access to experimental drug — but not in U.S.
San Francisco Business Times

Neuraltus Pharmaceuticals Inc. and a U.K. company inked a deal that opens access to the Palo Alto company’s experimental drug to patients with the potentially fatal muscle-zapping disease known as amyotrophic lateral sclerosis.

Financial terms of the deal weren’t disclosed.

In theory, programs like the one set up by Neuraltus and Clinigen Group plc’s Idis managed access unit are the proverbial win-win: Patients get early access to a drug that may (or may not) help them; and a company, as Neuraltus CEO Rich Casey explained to me earlier this year, gets reimbursed by payers and gets additional data about the drug.